Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients

Clinical Transplantation

Volumn 21, Issue 5, 2007, Pages 628-632

  Grim, Shellee A ^a   Pham, Thuy ^a   Thielke, James ^a   Sankary, Howard ^a   Oberholzer, Jose ^a   Benedetti, Enrico ^a   Clark, Nina M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

ABO incompatible; Infection; Positive cross match; Renal transplantation; Rituximab

Indexed keywords

ACICLOVIR; CEFAZOLIN; CLINDAMYCIN; COTRIMOXAZOLE; LEVOFLOXACIN; RITUXIMAB; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; AGED; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; ESOPHAGITIS; FEMALE; GRAFT INFECTION; GRAFT REJECTION; GRAFT SURVIVAL; HERPES SIMPLEX; HISTOINCOMPATIBILITY; HUMAN; KIDNEY TRANSPLANTATION; MALE; MEDICAL RECORD REVIEW; PERITONITIS; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; SURVIVAL RATE; UNITED STATES; URINARY TRACT INFECTION;

ABO BLOOD-GROUP SYSTEM; ADULT; AGED; ANTIBODIES, MONOCLONAL; BLOOD GROUPING AND CROSSMATCHING; CROSS INFECTION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 34548643899     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2007.00700.x     Document Type: Article

References (24)

1. Hume DM, Merrill JP, Miller BF et al. Experiences with renal homotransplantation in the human: Report of nine cases. J Clin Invest 1955: 34: 327.
2. Schnuelle P, van der Woude FJ. Should A2 kidneys be transplanted into B or O recipients? Lancet 1998: 351: 1675.
3. Starzl TE, Marchioro TL, Holmes JH et al. Renal homografts in patients with major donor-recipient blood group incompatibilities. Surgery 1964: 55: 195.
4. Stegall MD, Dean PG, Gloor JM. ABO-incompatible kidney transplantation. Transplantation 2004: 78: 635.
5. Alexandre GP, Squifflet JP, de Bruyere M et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 1987: 19: 4538.
6. Alexandre GP, de Bruyere M, Squifflet JP et al. Human ABO-incompatible living donor renal homografts. Neth J Med 1985: 28: 231.
7. Van Kampen CA, Roelen DL, Versteeg-van der Voort Maarschalk MF et al. Activated HLA class I-reactive cytotoxic T lymphocytes associated with a positive historical crossmatch predict early graft failure. Transplantation 2002: 74: 1114.
8. Gloor JM, De Goey SR, Pineda AA et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003: 3: 1017.
9. Gloor JM, Lager DJ, Moore SB et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003: 75: 971.
10. Alkhunaizi AM, de Mattos AM, Barry JM et al. Renal transplantation across the ABO barrier using A2 kidneys. Transplantation 1999: 67: 1319.
11. Shimmura H, T anabe K, I shikawa N et al. Role of anti-A/B antibody titers in results of ABO-incompatible kidney transplantation. Transplantation 2000: 70: 1331.
12. Nelson PW, Landreneau MD, Luger AM et al. Ten-year experience in transplantation of A2 kidneys into B and O recipients. Transplantation 1998: 65: 256.
13. Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000: 70: 887.
14. Schweitzer EJ, Wilson JS, Fernandez-Vina M et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000: 70: 1531.
15. Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 2002: 74: 1207.
16. Tyden G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003: 76: 730.
17. Johnson PW, Glennie MJ. Rituximab: Mechanisms and applications. Br J Cancer 2001: 85: 1619.
18. Sammartino C, Pham T, Panaro F et al. Successful simultaneous pancreas kidney transplantation from living-related donor against positive cross-match. Am J Transplant 2004: 4: 140.
19. Warren DS, Zachary AA, Sonnenday CJ et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant 2004: 4: 561.
20. Monteiro I, Mc Loughlin LM, Fisher A et al. Rituximab with plasmapheresis and splenectomy in ABO-incompatible liver transplantation. Transplantation 2003: 76: 1648.
21. Rituxan® Package Insert. Genentech, Inc. and IDEC Pharmaceuticals Corporation, South San Francisco, CA, 2003. 22.
22. Sharma VR, F leming DR, S lone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000: 96: 1184.
23. Isobe Y, Sugimoto K, Shiraki Y et al. Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy. Am J Hematol 2004: 77: 370.
24. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001: 345: 1000.